Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage biopharmaceutical company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, with a lead focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). This news page aggregates company-issued updates, press releases, and other coverage related to Pyxis Oncology’s oncology pipeline and corporate activities.
Readers can find announcements on preliminary and updated clinical data for micvotabart pelidotin (MICVO), the company’s first-in-concept ADC targeting extradomain-B of fibronectin in the tumor extracellular matrix. News items include results from Phase 1 monotherapy and Phase 1/2 combination studies in R/M HNSCC and other advanced solid tumors, as well as translational findings on MICVO’s three-pronged mechanism of action involving direct tumor cell killing, bystander effects, and immunogenic cell death.
In addition to clinical trial readouts, this feed features business and financial updates such as quarterly results, cash runway commentary, milestone payments from collaboration and license agreements, and information on royalty-related transactions. Corporate developments, including inducement equity grants, governance matters, and participation in investor and industry conferences, are also reflected in Pyxis Oncology’s news flow.
For investors, analysts, and others following PYXS, the news stream offers a consolidated view of how the company is advancing MICVO in monotherapy and in combination with pembrolizumab under a Clinical Trial Collaboration Agreement with Merck, as well as how it positions itself within the broader field of ADC-based cancer therapeutics. Regularly reviewing this page can help users track key clinical milestones, scientific presentations, and corporate disclosures that shape the company’s oncology development story.
Pyxis Oncology (Nasdaq: PYXS) has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024. Metzger brings over 25 years of biopharmaceutical experience and is currently the CEO of Syndax Pharmaceuticals. Pyxis CEO Lara S. Sullivan emphasized Metzger's expertise and leadership in innovation as vital for the company's growth, particularly in advancing their antibody-drug conjugates (ADCs) aimed at treating challenging cancers. Metzger expressed enthusiasm for contributing to Pyxis's mission of improving cancer treatment outcomes.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on next-generation cancer therapeutics, announced that its President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 AM Eastern Time in New York City. The management team will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available on the company's Investor Relations website.
Pyxis Oncology (Nasdaq: PYXS) announced its Q1 2024 financial results and corporate updates. PYX-201's Phase 1 trial has dosed 42 patients and aims to dose 16 more, with readout expected in fall 2024. PYX-106's Phase 1 trial, targeting NSCLC and other cancers, has dosed 24 patients, with data expected in 2H 2024. The company presented new preclinical data and expanded its leadership team with Stephen Worsley as Chief Business Officer. Q1 2024 financial highlights include revenues of $16.1M, R&D expenses of $13M, and a net loss of $3.3M. Cash runway is expected to last into 2H 2026.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be presenting at the RBC Capital Markets Global Healthcare Conference where the President and CEO will participate in a fireside chat and host investor meetings. The event will take place on May 14, 2024, at 3:05 PM ET.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.